Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy
The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.
Primary Sponsor
Collaborating Groups
Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)
Closing Date of Accrual
30 June 2019
Trial Chairperson
A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC
Trial Contact
nivorad@ctc.usyd.edu.au
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Related Post
Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers
SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr
TROG’s inaugural Km’s for Cancer Research brings community together to support our work
LATEST NEWS: 9 December 2025 As we wrap up